Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 23, 2020

Gilead halts emergency access to remdesivir in Covid-19 indication

Gilead Sciences has announced temporarily halt to emergency access to its investigational Covid-19 drug remdesivir due to rising demand.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Gilead Sciences has announced a temporary halt to emergency access to its investigational Covid-19 drug remdesivir due to rising demand.

The antiviral drug is currently being assessed in several clinical trials for treating the novel coronavirus infection.

For patients unable to participate in studies, the company has been working with regulators to offer emergency access to the drug.

Gilead noted that several hundred patients had been provided emergency access to remdesivir across the US, Europe and Japan.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

However, a recent surge in Covid-19 cases in the US and Europe led to an ‘exponential increase’ in compassionate use requests, added the company.

The company is switching from a system of individual compassionate-use requests to expanded access programmes to improve access to the drug for severely ill patients, as well as gather data from all participants.

Gilead will not accept new compassionate use requests during the transition period but will process previously approved requests. Exceptions will be made for pregnant women and children aged below 18 years with severe Covid-19 infection.

In a statement, the company said: “Enrolment in clinical trials is the primary way to access remdesivir to generate critical data that inform the appropriate use of this investigational medicine.

“We recognise the urgent need and are working to implement expanded access programmes as quickly as possible, with the continued support and collaboration of regulatory agencies.”

In February, the US National Institutes of Health (NIH) reported that remdesivir prevented the Middle East respiratory syndrome coronavirus (MERS-CoV) disease when administered in monkeys before infection, improving their condition after infection.

Gilead Sciences is an American biotechnology company that researches, develops and commercialises drugs, focusing primarily on antivirals to treat HIV, hepatitis B and C, as well as influenza.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU